Compositions of trem conjugates and uses thereof

WO2026080471A3PCT designated stage Publication Date: 2026-05-21FLAGSHIP PIONEERING INNOVATIONS VI LLC
View PDF 6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
FLAGSHIP PIONEERING INNOVATIONS VI LLC
Filing Date
2025-10-07
Publication Date
2026-05-21

AI Technical Summary

Technical Problem

Existing technologies face challenges in efficiently targeting and delivering therapeutic agents to specific tissues or cells, and in modulating protein expression in cells with premature termination codons, leading to diseases such as cancer and monogenic diseases.

Method used

Development of tRNA-based effector molecules (TREMs) conjugated with moieties like carbohydrates, proteins, peptides, lipids, or oligonucleotides, featuring non-naturally occurring modifications to enhance stability and targeting, and methods to modulate tRNA pools and protein expression.

Benefits of technology

Enhances tissue- and cell-specific delivery of therapeutic agents and increases protein expression by pairing with premature termination codons, effectively treating diseases associated with such codons.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The disclosure relates generally to tRNA-based effector molecules and conjugates thereof comprising moieties (e g., carbohydrates, lipids, peptides, small molecules, oligonucleotides) and methods, compositions, and uses relating thereto.
Need to check novelty before this filing date? Find Prior Art